Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCR 深 滬
已收盤 02-06 16:00:00 美东时间
31.98
+1.060
+3.43%
華盛通- 最 高32.93
- 今 開31.31
- 成交量 49.98万股
- 最 低 30.76
- 昨 收 30.92
- 總市值 16.16亿
- 52周最高 40.7147
- 市盈率 靜 --
- 換手率 0.99%
- 52周最低 23.15
- 委 比 17.50%
- 總股本 5053.04万
- 歷史最高 76.98
- 量 比 0.86
- 振 幅 7.02%
- 歷史最低 18.43
- 每 手 1
- 風險率 3.03%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 泰瑞达、Lumentum、哈贝尔、Enphase能源、西部数据获多家机构上调目标价；PayPal 、恩智浦、墨式烧烤遭多家机构下调目标价
今日重点评级关注：韦德布什：维持Replimune Group"跑赢大市"评级，目标价从18美元升至19美元；巴克莱：维持CytomX Therapeutics"超配"评级，目标价从8美元升至10美元
02-05 11:28
HC Wainwright & Co. Reiterates Buy on Immunocore Holdings, Maintains $100 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Immunocore Holdings (NASDAQ:IMCR) with a Buy and maintains $100 price target.
02-04 21:40
Moderna CMO Jacqueline Miller to step down
Moderna CMO Jacqueline Miller to step down Jan 30 (Reuters) - Moderna's MRNA.O Chief Medical Officer Jacqueline Miller, who led the development of the company's mRNA-based COVID-19 vaccine Spikevax , will step down effective March 2, the vaccine maker said on Friday. Miller joined Moderna in 2020 as
01-30 22:01
Immunocore announces R&D leadership evolution
<p>Immunocore Holdings plc宣布，其高级副总裁兼研发负责人Dr. David Berman将于2026年2月27日离职，转任另一大型生物技术公司的开发负责人。公司决定不直接 replacing him，而是优化其研发结构，倚重现有领导团队。Dr. Mohammed Dar（首席医疗官）和Mark Moyer（监管科学负责人）晋升为执行副总裁，分别接管临床开发及监管策略的扩展监督职责。CEO Bahija Jallal对Berman的贡献表示感谢，并对公司的研发实力和未来前景充满信心。Dar和Moyer均拥有丰富的行业经验，其晋升标志着公司致力于推进临床项目并为患者带来创新疗法。Immunocore专注于开发TCR双特异性免疫疗法，其首款药物KIMMTRAK已获39国批准，用于治疗特定晚期黑素瘤患者。</p>
01-30 12:00
Immunocore Sets 2026 Strategic Priorities for Melanoma Growth
Immunocore Holdings ( ($IMCR) ) has issued an announcement. On January 9, 2026,...
01-09 20:28
Immunocore announces 2026 strategic priorities at 44th Annual J.P. Morgan Healthcare Conference
Immunocore announced its 2026 strategic priorities at the 44th J.P. Morgan Healthcare Conference, including expanding KIMMTRAK's reach for metastatic uveal melanoma patients, completing enrollment in the TEBE-AM Phase 3 trial by mid-2026, presenting PRAME franchise data in ovarian and lung cancer, and advancing autoimmune and infectious disease candidates. The company also highlighted its financial position with $864 million in cash as of Decembe...
01-09 12:00
Immunocore Holdings Board Member Ranjeev Krishana Resigns
The latest announcement is out from Immunocore Holdings ( ($IMCR) ). On Novembe...
2025-11-28 20:28
美股大行评级 | 花旗上调英伟达目标价从210美元升至220美元；DraftKings、DoubleVerify遭多家大行下调目标价
今日重点评级关注：Guggenheim：维持InflaRx"买入"评级，目标价从10美元升至22美元；巴克莱：维持Tandem糖尿病护理"超配"评级，目标价从51美元升至55美元
2025-11-11 10:49
Morgan Stanley Maintains Equal-Weight on Immunocore Holdings, Raises Price Target to $36
Morgan Stanley analyst Andrew Galler maintains Immunocore Holdings (NASDAQ:IMCR) with a Equal-Weight and raises the price target from $34 to $36.
2025-11-11 01:54
Immunocore to present at upcoming investor conferences
Immunocore Holdings plc announced its participation in two healthcare conferences in November 2025. The Guggenheim 2nd Annual Healthcare Innovation Conference will feature a fireside chat on November 11, 2025, at 3:00 p.m. EST. Additionally, Immunocore will participate in the Jefferies London Healthcare Conference with a fireside chat on November 19, 2025, at 3:30 p.m. GMT. Presentations will be available live via webcast and on Immunocore’s webs...
2025-11-10 12:00
